Effects of ABCG2 knockdown on therapeutic enhancement of 5‐aminolevulinic acid with lapatinib
- 16 September 2026
- journal article
- research article
- Published by Wiley in Photochemistry and Photobiology
Abstract
5‐Aminolevulinic acid (ALA) is administered as a prodrug for tumor fluorescence detection and photodynamic therapy (PDT) after being converted endogenously to the active drug protoporphyrin IX (PpIX). As a substrate of the ABCG2 transporter, PpIX is subject to outward transport in cells with ABCG2 expression, resulting in reduced PpIX fluorescence and PDT effect. Due to the lack of approved ABCG2 inhibitors, lapatinib (Lap), a kinase inhibitor approved for cancer treatment, has been repurposed as an ABCG2 inhibitor for the enhancement of ALA. To provide evidence that Lap enhances ALA by inhibiting ABCG2, we knocked down ABCG2 in four tumor cell lines and evaluated the effects of Lap on enhancing ALA‐PpIX fluorescence and PDT in the wild‐type and ABCG2‐knockdown cell lines. ABCG2 knockdown enhanced ALA‐PpIX fluorescence and PDT response, underscoring the importance of ABCG2 in regulating intracellular PpIX accumulation. However, compared with the corresponding wild‐type cell lines, Lap induced less enhancement of PpIX fluorescence and PDT in ABCG2‐knockdown cell lines, particularly at high concentrations and in cell lines with low ABCG2 activities. By downregulating ABCG2 in tumor cells, we showed that Lap‐induced ALA enhancement was reduced, demonstrating that Lap enhances ALA by blocking ABCG2‐mediated PpIX efflux.Keywords
Funding Information
- National Institutes of Health (R15CA268200)
This publication has 17 references indexed in Scilit:
- Emerging uses of 5-aminolevulinic-acid-induced protoporphyrin IX in medicine: a review of multifaceted, ubiquitous, molecular diagnostic, therapeutic, and theranostic opportunitiesJournal of Biomedical Optics, 2025
- Enhancing PDT efficacy in NMIBC: Efflux inhibitor mediated improvement of PpIX levels and efficacy of the combination of PpIX‐PDT and SO‐cleavable prodrugsPhotochemistry and Photobiology, 2024
- Effectiveness of lapatinib for enhancing 5‐aminolevulinic acid‐mediated protoporphyrin IX fluorescence and photodynamic therapy in human cancer cell lines with varied ABCG2 activitiesPhotochemistry and Photobiology, 2024
- Targeting ABCG2 transporter to enhance 5-aminolevulinic acid for tumor visualization and photodynamic therapyBiochemical Pharmacology, 2023
- Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2Drug Resistance Updates, 2023
- Inhibition of ABCG2 transporter by lapatinib enhances 5-aminolevulinic acid-mediated protoporphyrin IX fluorescence and photodynamic therapy response in human glioma cell linesBiochemical Pharmacology, 2022
- Clinical uses of 5-aminolaevulinic acid in photodynamic treatment and photodetection of cancer: A reviewCancer Letters, 2020
- Evaluation of aminolevulinic acid-mediated protoporphyrin IX fluorescence and enhancement by ABCG2 inhibitors in renal cell carcinoma cellsJournal of Photochemistry and Photobiology B: Biology, 2020
- Revisiting the role of ABC transporters in multidrug-resistant cancerNature Reviews Cancer, 2018
- ABCG2 transporter inhibitor restores the sensitivity of triple negative breast cancer cells to aminolevulinic acid-mediated photodynamic therapyScientific Reports, 2015